Business Context and Reporting Period
Company: GAXOS.AI INC. (Ticker: GXAI)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Quarter and six months ended June 30, 2025
Business Overview: GAXOS.AI is a technology company developing AI-driven applications for gaming (Gaxos Gaming), generative AI for developers (Gaxos Labs), and health optimization (Gaxos Health/RNK Health). The company operates as a single segment and is classified as a smaller reporting company and an emerging growth company.
Key Financial Metrics
| Metric | Three Months Ended June 30, 2025 |
Six Months Ended June 30, 2025 |
Six Months Ended June 30, 2024 |
|---|---|---|---|
| Revenues | $170,971 | $194,703 | $19 |
| Operating Expenses | $1,153,665 | $2,569,092 | $1,898,361 |
| Loss from Operations | $(982,694) | $(2,374,389) | $(1,898,342) |
| Net Loss | $(824,572) | $(2,056,634) | $(1,721,383) |
| Net Loss Attributable to Common Shareholders | $(749,388) | $(1,941,188) | $(1,721,383) |
| Net Loss Per Share (Basic & Diluted) | $(0.11) | $(0.27) | $(1.60) |
| Cash and Cash Equivalents (End of Period) | $1,718,964 | $1,718,964 | $2,371,933 |
| Short-Term Investments | $12,326,666 | $12,326,666 | $2,167,419 |
| Working Capital | $13,992,440 | $13,992,440 | N/A |
| Net Cash Used in Operating Activities | N/A | $(2,014,345) | $(1,837,867) |
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased significantly from $19 in the six months ended June 30, 2024, to $194,703 in the same period in 2025. This growth is primarily driven by RNK Health's non-clinical administrative services ($192,950), with minor contributions from health coaching packages ($1,124), subscriptions ($607), and in-game items ($23).
- Operating Expenses: Total operating expenses rose 35.3% year-over-year for the six-month period, increasing from $1.90 million to $2.57 million.
- General and Administrative (G&A): Increased by 43.5% to $2.11 million, largely due to a $504,749 increase in advertising and marketing fees for RNK Health and a $250,000 increase in executive bonuses.
- Research and Development (R&D): Increased by 7.5% to $464,009, driven by development costs for Gaxos Health and RNK Health platforms.
- Investment Portfolio: Short-term investments surged from $2.17 million at year-end 2024 to $12.33 million as of June 30, 2025, reflecting a net cash outflow of $10.66 million in investing activities to purchase corporate bonds and funds.
- Intangible Assets: Intangible assets increased from $125,000 to $808,133 following the acquisition of software and technology licenses, partially paid for with 200,000 shares of common stock valued at $248,000.
Outlook, Risks, and Management Commentary
- Liquidity and Capital Resources: Management believes existing cash ($1.72 million) and short-term investments ($12.33 million) are sufficient to meet operating needs for the next 12 months. The company expects to continue generating operating losses due to corporate overhead, R&D, and public company costs.
- Strategic Initiatives:
- Gaxos Labs: Launched in September 2024 to provide generative AI tools for game developers.
- RNK Health: A 70% owned subsidiary providing non-clinical administrative services in partnership with a third-party medical management company. This is the primary current revenue driver.
- Risk Factors:
- Regulatory Risk: RNK Health's operations depend on a Medical Partner subject to evolving state laws regarding telehealth and medication management. Changes in regulations could materially adversely affect revenue.
- Profitability: The company has not yet achieved profitability and relies on future capital raises or revenue growth to sustain operations long-term.
- Concentration: Revenue is heavily concentrated in the RNK Health segment; gaming and subscription revenues remain negligible.
- Subsequent Events: On August 12, 2025, shareholders approved an amendment to the 2022 Equity Incentive Plan, increasing reserved shares to 803,637.
Investor Verification Checklist
- Revenue Sustainability: Verify the durability of RNK Health's partnership with the Medical Partner and the regulatory stability of the telehealth business model.
- Cash Burn Rate: Monitor the net cash used in operating activities ($2.01 million for six months) against the current cash and investment balance to assess runway.
- Investment Valuation: Review the composition and unrealized gains/losses of the $12.3 million short-term investment portfolio.
- Equity Dilution: Note the issuance of 200,000 shares for intangible assets and the existence of ~4.5 million outstanding warrants and ~139,000 stock options.
- Expense Management: Track the trajectory of G&A expenses, specifically marketing spend for RNK Health and executive compensation, relative to revenue growth.